CNTB - Connect Biopharma Holdings Limited... | Finranks

22.10.2026

Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround

Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

19.10.2026

Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher

Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

04.10.2026

Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures

Connect Biopharma NASDAQ: CNTB reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company said the study met its primary objective, showing reductions in treatment failures during the month after an exacerbation.

30.09.2026

Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy

Connect Biopharma Holdings Limited (NASDAQ:CNTB) recently shared positive topline results from its global Phase 2 study.

30.09.2026

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript

30.09.2026

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) –

16.09.2026

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript

Видео

No Data

There is no data to display

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
CNTB	Leerink Partners	Outperform	undefined >> $4	October 12th 2026

Пресс-релизы

30.09.2026

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) –

Connect Biopharma Holdings Limited (CNTB)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Контакты

Мы в соцсетях

Connect Biopharma Holdings Limited (CNTB)

Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround

Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher

Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures

Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Search stocks

Connect Biopharma Holdings Limited (CNTB)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Контакты

Мы в соцсетях

Connect Biopharma Holdings Limited (CNTB)

Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround

Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher

Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures

Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update